The financing follows a strategic shift for Orum, which shelved its original lead program and is now pursuing a potential ...

The fresh capital provides another shot for Moderna's candidate against bird flu, which earlier this year lost its government ...

The investment firm co-led a $125 million Series A round for Ambros Therapeutics, a Vivek Ramaswamy co-founded company with a ...

Despite being unable to declare statistical success, the company claimed its therapy showed enough promise to support moving ...

Recognizing the urgent need for treatment options and guided by patient insights, Pfizer scientists have discovered a way to ...

The approval could help Enhertu, which is already a multibillion-dollar seller, supplant a regimen that’s been the standard ...

Lilly’s closely watched retatrutide spurred as much as 29% weight loss in a Phase 3 study, a finding that is “raising the bar ...

Using a kind of novel linker technology, the startup is developing versions of incretin and non-incretin therapies that can ...

An unusual tussle over the availability of funds for Apple Tree’s startups led the firm to seek protection from creditors ...

The FDA placed the hold after researchers recorded a “higher than anticipated” incidence of deaths in a study testing “I-DXd” ...

The agency gave the green light to a U.S. company manufacturing Augmentin XR, an antibiotic first approved more than two ...

Analysts said the deal makes sense for BioMarin, as it offers a late-stage clinical asset as well as two marketed therapies ...